Type 2 Diabetes Pipeline Appears Promising With 75+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment
Explore our latest breakthroughs in Type 2 Diabetes Research. Learn more about our innovative pipeline today! @ Type 2 Diabetes Pipeline Outlook
Key Takeaways from the Type 2 Diabetes Pipeline Report
In July 2025, AstraZeneca announced a Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy.
In July 2025, Novo Nordisk A/S conducted a study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 2 diabetes. Participants will either get insulin icodec or insulin glargine.
In July 2025, Sanofi organized a Phase IV Single Arm Clinical Trial to Evaluate the Safety and Efficacy of a Fixed Ratio Combination of Insulin Glargine and Lixisenatide in Adult Patients With Type 2 Diabetes Who Are Sub Optimally Controlled on Oral Anti-hyperglycemic Drugs and/or Basal Insulin/GLP-1 RA.
In July 2025, Getz Pharma announced a study Objective To evaluate the safety and tolerability of Empagliflozin with or without metformin in patients with Type II Diabetes Mellitus in the Pakistani population.
DelveInsight's Type 2 Diabetes pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Type 2 Diabetes treatment.
The leading Type 2 Diabetes Companies such as Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Rivus Pharmaceuticals, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical and others.
Promising Type 2 Diabetes Pipeline Therapies such as Empagliflozin, Subetta, AZD6234, AZD1656, Glipizide, iGlarLixi (insulin glargine/lixisenatide), GFT505 80mg, Pioglitazone, Metformin, Sulfonylurea and others.
Stay informed about the cutting-edge advancements in Type 2 Diabetes treatments. Download for updates and be a part of the revolution in Endocrinology and Metabolic Disorders Care @ Type 2 Diabetes Clinical Trials Assessment
Type 2 Diabetes Emerging Drugs Profile
LY-3209590: Eli Lilly and Company
Insulin efsitora alfa (LY3209590) is a once-weekly basal insulin, a fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. It is specifically designed for once-weekly subcutaneous administration, and with its low peak-to-trough ratio, it has the potential to provide more stable glucose levels (less glucose variability) throughout the week. Efsitora is in phase III development for adults with type 1 and 2 diabetes.
THDB0206: Tonghua Dongbao Pharmaceutical
BC Lispro (THDB0206) is an ultra-rapid-acting insulin analog developed by Tonghua Dongbao Pharmaceutical Co., Ltd. for the treatment of type 2 diabetes. BC Lispro is designed to restore early-phase insulin secretion, which is often impaired in diabetic patients. This insulin analog utilizes a new formulation technology that allows for rapid absorption and action, mimicking the physiological pattern of insulin secretion after meals. Such characteristics are expected to reduce the risk of late postprandial hypoglycemia, providing patients with greater flexibility in managing their insulin injections. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Type 2 Diabetes.
HU6: Rivus Pharmaceuticals
Rivus Pharmaceuticals is developing HU6, a novel oral medication classified as a Controlled Metabolic Accelerator (CMA), aimed at treating various metabolic diseases, including type 2 diabetes. HU6 works by leveraging mitochondrial uncoupling to increase the body's resting metabolic rate, promoting fat loss while preserving lean muscle mass. Currently, the drug is in the Phase II stage of development to treat Type 2 Diabetes.
AZD-5004, also known as ECC5004, is an investigational small molecule glucagon-like peptide-1 receptor agonist (GLP-1RA) developed by AstraZeneca in collaboration with Eccogene. It is primarily aimed at treating obesity, type 2 diabetes, and related cardiometabolic conditions. AZD-5004 works by mimicking the effects of GLP-1, a hormone that regulates appetite and insulin secretion. This mechanism is crucial for managing weight and improving glucose metabolism, making it a potential therapeutic option for individuals with obesity and type 2 diabetes. Currently, the drug is in the Phase II stage of development to treat Type 2 Diabetes.
XW014: Sciwind Biosciences
XW014 is an oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist developed by Sciwind Biosciences for the treatment of obesity and type 2 diabetes (T2D). XW014 functions as a GLP-1 receptor agonist, which means it mimics the action of the GLP-1 hormone that is released after meals. This hormone plays a key role in regulating glucose metabolism by stimulating insulin secretion, inhibiting glucagon release, and promoting satiety. As an oral small molecule, XW014 offers advantages over traditional peptide-based GLP-1 therapies, such as ease of administration and the potential for combination therapies with other oral medications. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Type 2 Diabetes.
KN056: Suzhou Alphamab Co., Ltd.
KN-056 is a glucagon-like peptide-1 receptor (GLP-1R) modulator developed by Suzhou Alphamab Co., Ltd. for the treatment of type 2 diabetes. KN-056 functions as a GLP-1R modulator, which means it targets the glucagon-like peptide-1 receptor. GLP-1 is a hormone that plays a key role in regulating glucose metabolism by stimulating insulin secretion, inhibiting glucagon release, and promoting satiety. By modulating the GLP-1 receptor, KN-056 aims to improve glycemic control in patients with type 2 diabetes. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Type 2 Diabetes.
The Type 2 Diabetes Pipeline Report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Type 2 Diabetes with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Type 2 Diabetes Treatment.
Type 2 Diabetes Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Type 2 Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Type 2 Diabetes market.
Learn more about Type 2 Diabetes Drugs opportunities in our groundbreaking Type 2 Diabetes research and development projects @ Type 2 Diabetes Unmet Needs
Type 2 Diabetes Companies
Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Rivus Pharmaceuticals, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical and others.
Type 2 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Type 2 Diabetes Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Discover the latest advancements in Type 2 Diabetes treatment by visiting our website. Stay informed about how we're transforming the future of Endocrinology and Metabolic Disorders @ Type 2 Diabetes Market Drivers and Barriers, and Future Perspectives
Scope of the Type 2 Diabetes Pipeline Report
Coverage- Global
Type 2 Diabetes Companies- Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Rivus Pharmaceuticals, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical and others.
Type 2 Diabetes Pipeline Therapies- Empagliflozin, Subetta, AZD6234, AZD1656, Glipizide, iGlarLixi (insulin glargine/lixisenatide), GFT505 80mg, Pioglitazone, Metformin, Sulfonylurea and others.
Type 2 Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Type 2 Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Type 2 Diabetes Pipeline on our website @ Type 2 Diabetes Emerging Drugs and Companies
Table of Contents
Introduction
Executive Summary
Type 2 Diabetes: Overview
Pipeline Therapeutics
Therapeutic Assessment
Type 2 Diabetes– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
LY-3209590: Eli Lilly and Company
Mid Stage Products (Phase II)
HU6: Rivus Pharmaceuticals
Early Stage Products (Phase I)
KN056: Suzhou Alphamab Co., Ltd.
Preclinical and Discovery Stage Products
Drug name: Company name
Inactive Products
Type 2 Diabetes Key Companies
Type 2 Diabetes Key Products
Type 2 Diabetes- Unmet Needs
Type 2 Diabetes- Market Drivers and Barriers
Type 2 Diabetes- Future Perspectives and Conclusion
Type 2 Diabetes Analyst Views
Type 2 Diabetes Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/type-2-diabetes-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
9 minutes ago
- Globe and Mail
Why Some Investors Are Betting Big on Quantum Computing as a Moonshot Artificial Intelligence (AI) Play
Key Points Quantum technology is forecast to become a $200 billion market over the coming decades. One of the hottest stocks in the quantum movement is a company called Quantum Computing, which has seen its stock soar by nearly 3,000%. While it can be tempting to follow the enthusiasm, Quantum Computing's business deserves a thorough look before investing. 10 stocks we like better than Quantum Computing › While there are several major players fueling the artificial intelligence (AI) movement, perhaps none is more important than Nvidia. The company's industry-leading chipsets and sophisticated CUDA software application provide an end-to-end, tightly integrated ecosystem for many of the world's largest AI developers. The company's visionary CEO, Jensen Huang, has metaphorically referenced the rise of AI to that of an industrial revolution -- paving the way for a vast, ongoing runway of upside. Within the AI realm, a new pocket known as quantum computing is beginning to receive quite a bit of attention. While it's not commercially scaled today, quantum computing is believed by many technologists to contain transformative potential -- from accelerating drug discovery to enhancing machine learning capabilities. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » One company that has benefited greatly from the bullish rhetoric surrounding quantum applications is a company fittingly called Quantum Computing (NASDAQ: QUBT). With shares up nearly 3,000% over the last year, could Quantum Computing be the next big moonshot to pay off during the AI-themed industrial revolution? Quantum computing could completely revolutionize the AI storyline, but... Global management consulting firm McKinsey & Company categorizes quantum technology across three major applications: quantum computing, quantum communication, and quantum sensing. According to its forecasts, the quantum computing market could be worth up to $72 billion by 2035, while the total quantum technology market could reach closer to $200 billion by 2040. With the potential to disrupt end markets across robotics, climate tech, cybersecurity, healthcare, and cryptography, it's not entirely surprising that AI's leading developers, such as Nvidia, Microsoft, Amazon, Alphabet, and IBM, are all exploring quantum computing in various ways -- from developing next-generation chips to supercomputers. ... investors should be very careful as to which companies deserve attention Anytime a stock rises as sharply as Quantum Computing's has -- and seemingly out of nowhere to boot -- it's usually a good idea to investigate why. Earlier this year, I wrote a deep dive on Quantum Computing's corporate history. To summarize, the company was once doing business as Innovative Beverage Group Holdings (IBGH). At the risk of stating the obvious, this has nothing to do with quantum computing. After an unsuccessful venture in the beverage market, which was later followed by lawsuits from investors, IBGH rebranded as Quantum Computing. While such a transformation may appear odd, it's actually not as uncommon as you might think. Back in 2017, a relatively unknown beverage company known as Long Island Iced Tea Corp. rebranded as Long Blockchain. The rebrand was marketed as a strategic shift in the company's business -- transitioning from a beverage company to one focused on Bitcoin mining. These efforts never panned out, and Long Blockchain was delisted from the Nasdaq exchange. Along similar lines, companies struggling with growth such as GameStop and Strategy (formerly known as MicroStrategy) have managed to stay relevant and win investor enthusiasm by adding Bitcoin to their balance sheet. QUBT Revenue (TTM) data by YCharts Over the last year, Quantum Computing has generated less than half a million dollars in sales. And yet the company managed to burn through $45 million. This is an upside-down financial profile, regardless of its industry. I have serious doubts over Quantum Computing's technological foundation and its ability to compete in such a sophisticated, capital-intensive industry against the likes of big tech. Is Quantum Computing stock a buy? The reason I highlighted these examples is that changes in corporate narratives can be more performative than strategic to the underlying business. In other words, companies such as GameStop, Strategy, and Quantum Computing are using hot trends to capitalize on hype narratives as opposed to actually developing a concrete plan rooted in long-term value creation. Quantum technology could be seen as a venture capital -style investment opportunity -- one that carries asymmetric upside relative to its risk profile. Given how little traction Quantum Computing (the business) has generated so far in combination with its seemingly directionless roadmap, I do not see the stock as a moonshot opportunity. Instead, I view Quantum Computing stock as a highly speculative opportunity masquerading as an innovative play on one of AI's next megatrends. For these reasons, I would pass on investing in Quantum Computing stock. Should you invest $1,000 in Quantum Computing right now? Before you buy stock in Quantum Computing, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Quantum Computing wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,774!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,942!* Now, it's worth noting Stock Advisor's total average return is 1,040% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025
Globe and Mail
9 minutes ago
- Globe and Mail
Lee Chambers recognised as an 2025 inspirational D&I leader
The CEO of Male Allies UK was featured on the 2025 D&I Leaders most inspirational list Lee Chambers, the business psychologist and CEO of Male Allies UK, was nominated in a survey of 370 international diversity and inclusion professionals as an inspirational leader in the field of gender equality and male allyship. The list recognises who people in the profession see as thought leaders who are accelerating workplace inclusion across the globe. Chambers features on this year list for the first time, and is joined by other practitioners whose focus on evidence based inclusion stands out in the current climate. This years list includes John Amaechi, Pamela Hutchinson and Zaheer Ahmad. The list, in it's 5th year, is one of the most prestigious pieces of recognition for those in the field of inclusion, given it solely selected by peers across the globe. Diversity and Inclusion Leaders are a community of over 20,000 people, in roles relating to inclusion and those passionate about people and culture within organisations. They host a yearly summit and a range of expert led events across the calendar year, designed to upskill and equip leaders while fostering connection across industries. On featuring on this years list, Lee Chambers said, "To be recognised and held up by those that work in the field is a moment to remember on my journey. Male Allies UK may only be a year old, but years of work have gone into ensuring we are impactful, relevant and innovative, and create outcomes that last for our clients. I wouldn't class myself as inspirational, but I do feel inspired by the difference we have made. This is my peers telling me to keep going, and I get fulfillment and energy from that." This caps an excited first half of the year for the Male Allies UK team, and with the launch of their Voice of the Boys report in the House of Commons and collaborations with global companies across 12 sectors, they are just getting starting in making male allyship and gender equity a reality.
Globe and Mail
34 minutes ago
- Globe and Mail
IBM Exceeds Q2 2025 Expectations with Strong Growth
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. International Business Machines ( (IBM)) just unveiled an announcement. IBM reported strong financial results for the second quarter of 2025, with revenue, profit, and cash flow exceeding expectations. The company's performance was driven by growth in its Software and Infrastructure segments, particularly with the introduction of the z17 mainframe and advancements in AI and hybrid cloud solutions. IBM's strategic focus on AI and hybrid cloud continues to yield positive outcomes, as evidenced by significant growth in its GenAI business and recognition as an Emerging Leader in AI consulting. The company also expanded its partner ecosystem and launched new capabilities in its watsonx portfolio, further solidifying its position in the technology industry. The most recent analyst rating on (IBM) stock is a Buy with a $250.00 price target. To see the full list of analyst forecasts on International Business Machines stock, see the IBM Stock Forecast page. Spark's Take on IBM Stock According to Spark, TipRanks' AI Analyst, IBM is a Outperform. IBM's overall stock score is driven by strong financial performance and positive technical indicators, highlighting robust growth in software and AI. Valuation concerns due to a high P/E ratio and macroeconomic challenges in consulting and infrastructure present potential risks. Nonetheless, strategic initiatives and financial flexibility position IBM well for continued growth. To see Spark's full report on IBM stock, click here. International Business Machines (IBM) is a leading technology company operating in the software, infrastructure, and consulting sectors. The company focuses on hybrid cloud and artificial intelligence (AI) solutions, with a strong emphasis on innovation, client trust, and a broad ecosystem to drive growth. Average Trading Volume: 3,767,706 Technical Sentiment Signal: Buy Current Market Cap: $262.1B For an in-depth examination of IBM stock, go to TipRanks' Overview page.
